ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors...

ARYA Sciences Acquisition Corp IV Announces Pricing of $130 Million Initial Public Offering NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (the “Company”), a special purpose acquisition company formed for the purpose of entering into a combination with one or...